Scios' Natrecor is approvable in USA
Scios has received an approvable letter from the US Food and DrugAdministration for Natrecor (nesiritide), its intravenous treatment for patients with acutely-decompensated congestive heart failure. The company is now in the final stages of preparing for full approval of the drug, which is dependent on finalization of Natrecor's labeling and completion of an inspection of manufacturing facilities.
Natrecor is expected to be launched in the third quarter of this year, when it will become the first drug from the US firm to reach the market and the first new agent for CHF in more than 10 years. The schedule for the introduction of Natrecor is a little later than the company had hoped, having earlier said it planned to launch it in the USA this month. Analysts have suggested that Natrecor could achieve sales of around $300 million at peak.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze